---
created: '2026-02-13T17:49:23.724064Z'
description: A novel tau biomarker from the microtubule-binding region that specifically
  reflects tau tangle pathology and neurodegeneration. May outperform p-tau217 for
  tracking disease progression and treatment response.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/biomarker/mtbr-tau243/
slug: mtbr-tau243
tags:
- biomarker
- csf
- plasma
- tau
- cutting-edge
- tangles
- 2024-research
templateEngineOverride: njk
title: MTBR-tau243
type: biomarker
updated: '2026-02-13T17:49:23.724064Z'
---

{% raw %}
<h1>MTBR-tau243</h1>
<h2>Overview</h2>
<p>MTBR-tau243 is a novel tau biomarker comprising fragments from the microtubule-binding region (MTBR) of tau that are released specifically during neurofibrillary tangle formation and neurodegeneration. Unlike phospho-tau species (p-tau181, p-tau217) that reflect both amyloid-induced tau secretion and tangles, MTBR-tau is more specifically tied to tangles and disease progression. This may make it superior for tracking treatment response and predicting decline.</p>
<h2>Scientific Basis</h2>
<h3>Tau Structure and Release</h3>
<pre><code>N-terminus ---- Mid-domain ---- MTBR ---- C-terminus
     ↓              ↓            ↓
 p-tau181      p-tau217      MTBR-tau243
     ↓              ↓            ↓
Soluble tau   Tau secretion   Tangle-derived
 (early)       (amyloid-      (neurodegeneration)
               induced)
</code></pre>
<h3>Why MTBR-tau Is Different</h3>
<table>
<thead>
<tr>
<th>Feature</th>
<th>p-tau181/217</th>
<th>MTBR-tau243</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reflects</td>
<td>Tau phosphorylation, amyloid response</td>
<td>Tangle pathology, neurodegeneration</td>
</tr>
<tr>
<td>Elevation timing</td>
<td>Early (preclinical)</td>
<td>Later (with tangles)</td>
</tr>
<tr>
<td>Correlation with</td>
<td>Amyloid PET</td>
<td>Tau PET, atrophy</td>
</tr>
<tr>
<td>Prognosis</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
<tr>
<td>Treatment tracking</td>
<td>May decrease with anti-amyloid</td>
<td>Reflects neuronal loss</td>
</tr>
</tbody>
</table>
<h2>Key Research Findings</h2>
<h3>Barthélemy et al. (2020, Nature Medicine)</h3>
<ul>
<li>First characterization of MTBR-tau species</li>
<li>CSF MTBR-tau correlates with tau PET</li>
<li>Distinguishes AD stages better than p-tau</li>
</ul>
<h3>DIAN Cohort Studies</h3>
<ul>
<li>Elevated later in disease than p-tau217</li>
<li>Correlates with cognitive decline</li>
<li>Predicts future atrophy</li>
</ul>
<h3>Biomarker Staging</h3>
<table>
<thead>
<tr>
<th>Stage</th>
<th>p-tau217</th>
<th>MTBR-tau243</th>
<th>Clinical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preclinical (amyloid+)</td>
<td>Elevated</td>
<td>Normal-mild ↑</td>
<td>Normal cognition</td>
</tr>
<tr>
<td>Prodromal MCI</td>
<td>Elevated</td>
<td>Elevated</td>
<td>Memory symptoms</td>
</tr>
<tr>
<td>AD dementia</td>
<td>Elevated</td>
<td>Highly elevated</td>
<td>Dementia</td>
</tr>
</tbody>
</table>
<h2>Clinical Applications</h2>
<h3>Potential Advantages Over p-tau217</h3>
<ol>
<li><strong>Staging</strong>: Distinguishes early from advanced disease</li>
<li><strong>Prognosis</strong>: Stronger correlation with future decline</li>
<li><strong>Treatment monitoring</strong>: Reflects ongoing neurodegeneration</li>
<li><strong>Tau-specific</strong>: Less influenced by amyloid-only changes</li>
</ol>
<h3>Proposed Uses</h3>
<table>
<thead>
<tr>
<th>Application</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease staging</td>
<td>Differentiates preclinical from symptomatic</td>
</tr>
<tr>
<td>Prognosis</td>
<td>Predicts rate of decline</td>
</tr>
<tr>
<td>Treatment trials</td>
<td>Outcome measure for anti-tau therapies</td>
</tr>
<tr>
<td>Treatment monitoring</td>
<td>Track neurodegeneration on anti-amyloid</td>
</tr>
</tbody>
</table>
<h2>Measurement</h2>
<h3>Current Methods</h3>
<ul>
<li><strong>IP-LC-MS/MS</strong>: Immunoprecipitation + mass spectrometry</li>
<li>Washington University protocols</li>
<li>Research use only</li>
<li>Technically demanding</li>
</ul>
<h3>Challenges</h3>
<ul>
<li>Mass spectrometry required (not immunoassay)</li>
<li>Limited lab availability</li>
<li>Standardization in progress</li>
<li>Not yet FDA approved</li>
</ul>
<h3>Emerging Platforms</h3>
<ul>
<li>Immunoassays in development</li>
<li>Potential for broader availability</li>
<li>Clinical implementation years away</li>
</ul>
<h2>Comparison: MTBR-tau vs p-tau217 vs t-tau</h2>
<table>
<thead>
<tr>
<th>Feature</th>
<th>p-tau217</th>
<th>MTBR-tau243</th>
<th>Total tau</th>
</tr>
</thead>
<tbody>
<tr>
<td>Best for</td>
<td>AD diagnosis</td>
<td>Staging, prognosis</td>
<td>General neurodegeneration</td>
</tr>
<tr>
<td>Specificity for AD</td>
<td>Very high</td>
<td>High</td>
<td>Low</td>
</tr>
<tr>
<td>Tangle correlation</td>
<td>Moderate</td>
<td>Strong</td>
<td>Moderate</td>
</tr>
<tr>
<td>Amyloid influence</td>
<td>Strong</td>
<td>Less</td>
<td>Minimal</td>
</tr>
<tr>
<td>Availability</td>
<td>Emerging clinical</td>
<td>Research only</td>
<td>Established</td>
</tr>
</tbody>
</table>
<!-- NEO4J_CONTENT_START -->
<h2>Relationships</h2>
<h3>Related</h3>
<ul>
<li>← <a href="/garden/dev_admin/pathway/tau-phosphorylation/" class="internal-link">Tau_Phosphorylation</a> (pathway)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:48:42.217327'
source: obsidian
</code></pre>
<ul>
<li>← <a href="/garden/dev_admin/pathway/neuroinflammation/" class="internal-link">Neuroinflammation</a> (pathway)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:48:41.332585'
source: obsidian
</code></pre>
<ul>
<li>← <a href="/garden/dev_admin/condition/frontotemporal-dementia/" class="internal-link">Frontotemporal_Dementia</a> (condition)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:38.556708'
source: obsidian
</code></pre>
<ul>
<li>← <a href="/garden/dev_admin/condition/alzheimers-disease/" class="internal-link">Alzheimers_Disease</a> (condition)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:30.206636'
source: obsidian
</code></pre>
<ul>
<li>← <a href="/garden/dev_admin/biomarker/total-tau/" class="internal-link">Total_Tau</a> (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:24.002967'
source: obsidian
</code></pre>
<ul>
<li>← <a href="/garden/dev_admin/biomarker/plasma-p-tau217/" class="internal-link">Plasma_p-tau217</a> (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:22.556335'
source: obsidian
</code></pre>
<ul>
<li>← <a href="/garden/dev_admin/biomarker/neurofilament-light-chain/" class="internal-link">Neurofilament_Light_Chain</a> (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:20.980878'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/condition/frontotemporal-dementia/" class="internal-link">Frontotemporal_Dementia</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:20.593328'
source: obsidian
</code></pre>
<ul>
<li>→ <a class="internal-link is-unresolved" href="/404">Progressive_Supranuclear_Palsy</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:20.593328'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/biomarker/total-tau/" class="internal-link">Total_Tau</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:20.593328'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/examination/tau-pet-imaging/" class="internal-link">Tau_PET_Imaging</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:20.593328'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/biomarker/plasma-p-tau217/" class="internal-link">Plasma_p-tau217</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:20.593328'
source: obsidian
</code></pre>
<ul>
<li>→ <a class="internal-link is-unresolved" href="/404">Alzheimers_Disease</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:20.593328'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/biomarker/neurofilament-light-chain/" class="internal-link">Neurofilament_Light_Chain</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:20.593328'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/pathway/tau-phosphorylation/" class="internal-link">Tau_Phosphorylation</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:20.593328'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/pathway/tau-phosphorylation/" class="internal-link">Tau_Phosphorylation</a> (pathway)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:14.924796'
source: obsidian
</code></pre>
<ul>
<li>→ <a class="internal-link is-unresolved" href="/404">Progressive_Supranuclear_Palsy</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:14.924796'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/pathway/neuroinflammation/" class="internal-link">Neuroinflammation</a> (pathway)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:14.924796'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/biomarker/plasma-p-tau217/" class="internal-link">Plasma_p-tau217</a> (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:14.924796'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/condition/alzheimers-disease/" class="internal-link">Alzheimers_Disease</a> (condition)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:14.924796'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/biomarker/neurofilament-light-chain/" class="internal-link">Neurofilament_Light_Chain</a> (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:14.924796'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/examination/tau-pet-imaging/" class="internal-link">Tau_PET_Imaging</a> (examination)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:14.924796'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/condition/frontotemporal-dementia/" class="internal-link">Frontotemporal_Dementia</a> (condition)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:14.924796'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/biomarker/total-tau/" class="internal-link">Total_Tau</a> (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:14.924796'
source: obsidian
</code></pre>
<!-- NEO4J_CONTENT_END -->
<h2>Relationships</h2>
<h3>Conditions</h3>
<ul>
<li>→ <a href="/garden/dev_admin/condition/alzheimers-disease/" class="internal-link">Alzheimer's Disease</a> (condition) - <em>Staging and prognosis</em></li>
<li>→ <a href="/garden/dev_admin/condition/frontotemporal-dementia/" class="internal-link">Frontotemporal Dementia</a> (condition) - <em>Tauopathy marker</em></li>
<li>→ <a href="/garden/dev_admin/condition/progressive-supranuclear-palsy/" class="internal-link">Progressive Supranuclear Palsy</a> (condition) - <em>4R tauopathy research</em></li>
</ul>
<h3>Related Biomarkers</h3>
<ul>
<li>→ <a href="/garden/dev_admin/biomarker/plasma-p-tau217/" class="internal-link">Plasma p-tau217</a> (biomarker) - <em>Complementary, earlier</em></li>
<li>→ <a href="/garden/dev_admin/biomarker/total-tau/" class="internal-link">Total Tau</a> (biomarker) - <em>Less specific</em></li>
<li>→ <a href="/garden/dev_admin/biomarker/neurofilament-light-chain/" class="internal-link">Neurofilament Light Chain</a> (biomarker) - <em>Neurodegeneration correlate</em></li>
<li>← <a href="/garden/dev_admin/examination/tau-pet-imaging/" class="internal-link">Tau PET Imaging</a> (examination) - <em>Strong correlation</em></li>
</ul>
<h3>Pathways</h3>
<ul>
<li>→ <a href="/garden/dev_admin/pathway/tau-phosphorylation/" class="internal-link">Tau Phosphorylation</a> (pathway) - <em>Source of fragments</em></li>
<li>→ <a href="/garden/dev_admin/pathway/neuroinflammation/" class="internal-link">Neuroinflammation</a> (pathway) - <em>Tangle-associated</em></li>
</ul>
<h2>ATN(D) Framework Extension</h2>
<h3>Proposed Addition</h3>
<ul>
<li><strong>A</strong>: Amyloid (Aβ42/40, amyloid PET)</li>
<li><strong>T</strong>: Tau pathology (p-tau217)</li>
<li><strong>N</strong>: Neurodegeneration (NfL, t-tau)</li>
<li><strong>D</strong>: Disease stage/progression (MTBR-tau243?)</li>
</ul>
<h3>Staging Potential</h3>
<pre><code>A+T-N- → A+T+N- → A+T+N+ with low MTBR → A+T+N+ with high MTBR
(Preclinical) (Early)   (Early symptoms)    (Progressive disease)
</code></pre>
<h2>Future Directions</h2>
<h3>Clinical Development Path</h3>
<ol>
<li>Standardized mass spec protocols</li>
<li>Reference materials and cutoffs</li>
<li>Immunoassay development</li>
<li>Clinical validation trials</li>
<li>FDA regulatory pathway</li>
</ol>
<h3>Anticipated Timeline</h3>
<ul>
<li>Research refinement: 2024-2026</li>
<li>Immunoassay availability: 2026-2028</li>
<li>Clinical implementation: 2028+</li>
</ul>
<h3>Blood-Based MTBR-tau</h3>
<ul>
<li>Under investigation</li>
<li>More challenging than CSF</li>
<li>Would enable accessible staging</li>
</ul>
<h2>References</h2>
<ol>
<li><strong>Original Discovery</strong>: Barthélemy, N.R., et al. (2020). &quot;A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited AD.&quot; <em>Nature Medicine</em>.</li>
<li><strong>DIAN Data</strong>: Barthélemy, N.R., et al. (2023). &quot;CSF tau species for staging AD.&quot; <em>Nature Reviews Neurology</em>.</li>
<li><strong>Clinical Implications</strong>: Bateman, R.J., et al. (2023). &quot;Tau biomarker staging of AD.&quot; <em>Annals of Neurology</em>.</li>
</ol>

{% endraw %}